Ro(SSA) is an intracellular ribonucleoprotein against which autoantibodies are found in a portion of patients with Sjogren's syndrome and systemic lupus erythematosus.
Introduction
Systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS)' are diseases of unknown etiology and uncertain pathogenesis. A common characteristic of these diseases is the production of autoantibodies, among which anti-Ro(SSA) is found in both conditions. Using sensitive ELISA methodology, elevated levels ofanti-Ro(SSA) have been detected in 49% of SLE patients and up to 96% of SS patients (1, 2) .
In nucleated human cells, Ro(SSA) has been described as a 60-kD protein associated with one of four RNAs of 83-112 bases, termed hY RNAs (3, 4) . This particle of unknown function is detected and affinity purified using isolated IgG from patients with SLE and SS. Initially, Ro(SSA) and its antibody have been defined solely on the basis of gel diffusion (Ouchterlony) using monospecific prototype serum. Now, in addition to the serological definition, the association of the Ro(SSA) protein with hY RNAs has been used as a characteristic property (3, 4) . Ro(SSA) has been described in several human tissues and tissues from lower animals using several different techniques (4) (5) (6) (7) (8) (9) . Whereas differences have been found in the structure and quantity of Ro(SSA) across species barriers (4, 5, 8) , molecular differences have not previously been described between Ro(SSA) from different tissues and cell types in the same species (4) . In this report we describe structural differences in Ro(SSA) obtained from human lymphocytes and red blood cells.
Methods
Cell samples and separation. Human blood cells were isolated from fresh heparinized blood samples from healthy donors using the procedure accompanying Histopaque-1077 (Sigma Chemical Co., St. Louis, MO). Lymphocytes were obtained in the top layer and frozen in liquid nitrogen for viability in freezing media (RPMI 1640; Irvine Scientific, Santa Ana, CA) + 20% AB serum + 7.5% DMSO + 1% penicillin/ streptomycin + 1% L-glutamine). For some of the experiments, lymphocytes were obtained from leukophoresis of a patient with chronic lymphocytic leukemia. Lymphocyte-depleted red blood cells were washed three times by adding an equal volume ofPBS and centrifuging at 500 g for 10 min. After each wash, the buffy coat was removed to further deplete the red cells of contaminating granulocytes. Granulocytes were isolated using hydroxy-ethylstarch, Hespan (American Hospital Supply, Irvine, CA), and Ficoll-Hypaque with Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden), which has been described elsewhere (10) . The red cells were packed at a concentration of 8 X 106 cells/mm3 by centrifugation at 500 g for 20 min after the last wash. They were stored at -30'C, packed, and overlayered with PBS.
Lysate preparation. Lymphocytes were thawed and the DMSO was immediately diluted out in 10 vol of PBS. The cells were pelleted to a concentration of 106 cells/mm3 by centrifugation at 500 g for 5 min. Granulocytes were used freshly isolated and pelleted by centrifugation at 500 g for 5 min. Because isolated red cells were frozen packed in large volumes (50 ml), small aliquots were obtained by using an Ouchterlony well punch to core sample the frozen packed cells. Lysis was achieved by adding 2 SDS-PAGE. 10% polyacrylamide gels with 4.5% polyacrylamide stacking gels, both with 0.1% SDS were run using the discontinuous buffer method previously described ( 16) .
Western immunoblotting. A method described previously (17, 18) was modified to use with a semidry blotting apparatus (American Bionetics, Emeryville, CA with antisera as in the Western blot procedure. The method for the elution of antibodies has been described (19, 20) . The eluate was dialyzed to PBS by repeated dilution and concentration using the concentration device as recommended by the manufacturer (Centriprep; Amicon Corp., Danvers, MA).
Counterimmunoelectrophoresis was performed as previously described (2 1).
Results
Using a sensitive sandwich ELISA, Ro(SSA) was detected in lysates prepared from isolated red cells and lymphocytes.
Lymphocytes isolated from normal individuals and a patient with chronic lymphocytic leukemia were found to have the same properties. The optical density obtained was inhibitable by more than 50% by preincubation ofthe secondary antibody with 0.1 mg/ml of affinity-purified bovine Ro(SSA) described previously (14) . By counting the cells used to make the lysates, the number of lymphocytes that would produce a lysate of a particular optical density could be calculated and compared with the number of red cells that would produce a lysate having a similar optical density by ELISA. The amount of lymphocyte contamination necessary to account for Ro(SSA) in the red cell lysate was found to be 0.41%. Before separation, the percentage of lymphocytes in blood when compared with red cells is 0.07%. This means that a sixfold enrichment of lymphocytes in whole blood would be necessary to explain the results on the basis of contamination. This calculation further bolsters our contention that the Ro(SSA) measured in red cell extracts derives from red cells and cannot be accounted for by either lymphocyte or granulocyte contamination.
RNA extraction of protein A-assisted immunoprecipitates showed Ro(SSA) in red cells is associated with two populations of hY RNAs (Fig. 2) . Others have described four hY RNAs in nucleated cells; hYl, hY3, hY4, and hY5 (hY2 is a truncated form of hYl) (4, 20) . One of the Ro(SSA)-associated RNA species in red cells migrates between hYl and hY2; the other comigrates with hY4. Whether these RNAs are identical remains to be determined. In red cell lysates contaminated with lymphocytes, faint hY3 and hY5 bands were detectable. These data firmly establish that the Ro(SSA) in the red cell lysate did not derive from lymphocyte or other leukocyte contamination. The ratio of red cell to lymphocyte lysate that resulted in equivalent amounts of Ro(SSA) as detected by native assays (ELISA, immunodiffusion, RNA immunoprecipitation) was 30-60:1. Red cell Ro(SSA) antigenicity in assays reflecting native structure (ELISA, gel diffusion, immunoprecipitation) was unstable and activity was lost with any preparative maneuver.
Different results were obtained when Western immunoblots of reduced CM-52 extracts were run on SDS-polyacrylamide gels. Here, equal amounts of lymphocyte and red cell extracts yielded equivalent signals with serum samples that contained antibodies that reacted with Ro(SSA) from both sources. In addition to this difference in antigenicity reflecting assays of native and denatured forms, somewhat different molecular weight proteins were detected using lymphocyte and red cell extracts. Monospecific autoimmune sera, all of which gave a Ro(SSA) precipitin line in gel diffusion with bovine spleen extracts, reacted with 60-and 54-kD forms from human red cell lysates, whereas human lymphocyte lysates showed 60-and 52-kD forms (Fig. 3) . The specificity ofthese antigenically active proteins was demonstrated by the lack of reactivity with other anti-Ro(SSA) sera (Fig. 4) . As can be seen, serum Wa binds the lymphocyte 60-kD band but not the red cell 60-kD band, whereas serum Ha binds the red cell Ro 60-kD but not the lymphocyte 60-kD band. Serum St binds both the lymphocyte 52-kD band and the red cell 54-kD band. Almost all precipitating anti-Ro(SSA) sera that bind the 52-kD lymphocyte band also bind the red cell 54-kD band, but we have several anti-Ro(SSA) sera that bind the red cell 54-kD band that do not bind the lymphocyte 52-kD band. Sera that bound only the 54-kD or only the 60-kD form in Western blot were used to immunoprecipitate the ribonucleoprotein and the as- sociated hY RNAs were extracted with phenol/chloroform (Fig. 5) . Also seen in this figure in lanes 2 and 3 are the red cell Ro RNAs brought down by serum 571, a rabbit antiserum prepared against affinity-purified human red cell Ro(SSA).
To ensure that the antibody in the serum that bound the RNA-associated protein was the same as the antibody that bound the two bands on Western blot, the affinity-isolated antibodies from the two bands were used to immunoprecipi- tate the particle. The associated hY RNAs were then extracted. The affinity-isolated antibody immunoprecipitated the same two hY RNAs (hYl and hY4) from red cell lysates (data not shown), providing strong evidence that the antibodies in the serum that bound these two bands were anti-Ro(SSA). These affinity-purified antibodies also bound Ro(SSA) in nucleated cells evidenced by the recovery of hY4 and hY5 in extracts of immunoprecipitates using HeLa cells, but the gels were too light to detect the minor RNA species hY I and hY3. In summary, antigenic differences were detected between all four forms of Ro(SSA) using autoimmune sera. Sera from some patients were found to react exclusively with one and not with others, for all four forms 60-and 52-kD in the lymphocyte, and 60-and 54-kD in the red cell (Fig. 4) .
A sandwich ELISA was developed using a heteroantiserum raised in a rabbit against purified bovine Ro(SSA) (21) . Using this assay we found the Ro(SSA) in red cell lysates was antigenically deficient to lymphocyte lysates that had equivalent amounts based on an ELISA using autoimmune sera (Fig. 6) . The rabbit anti-bovine Ro(SSA) was thus able to detect differences in Ro(SSA) from the two cell types evaluated which had reacted in an equivalent fashion with human autoantibody.
Finally, two rabbit anti-red cell Ro(SSA) sera have been prepared that show the reciprocal result; lymphocyte Ro(SSA) is antigenically deficient to red cell Ro(SSA) in sandwich ELISA. Details ofthese sera will be reported elsewhere. Briefly, these sera bind only the 60-kD red cell Ro(SSA) band in Western blot and immunoprecipitate Ro(SSA) RNAs hYl and hY4 from red cell lysates (Fig. 5 60-genic differences between the four different types of Ro(SSA) protein described here.
Discussion
The major finding reported here is the identification of alternate forms of Ro(SSA) in the red blood cell. Others have used various methods to detect Ro(SSA) in a variety of tissues and cell types from different sources (4, 5, 8) . The use of a sensitive sandwich ELISA revealed detectable quantities of Ro(SSA) in crude lysates from red blood cells and lymphocytes. This activity was attributed to Ro(SSA) because concentrated extracts from red blood cells and lymphocytes precipitated with antiRo(SSA) in counterimmunoelectrophoresis, and the binding in ELISA was inhibited by more than 50% by affinity-purified bovine Ro(SSA). Additionally, Western blot analysis revealed two molecular forms of Ro(SSA) in the red cell. The 60-kD band was partially inhibited by preincubating serum with purified Ro(SSA) from human spleen and both the 60-and 54-kD bands were shown to be Ro(SSA) by using the affinity-isolated IgG from the Western blot bands to immunoprecipitate the Ro(SSA)-associated RNAs from both red cell and lymphocyte lysates.
Comparing the ELISA activity of Ro(SSA) detected in lymphocytes using purified bovine spleen Ro(SSA) as a standard, weight units were calculated. The concentration of affinity-purified Ro(SSA) was determined by a dye binding assay Because of the difference in antigenicity between lymphocytes and red cells, a similar calculation for red cells is not possible. The similarity between the Ro(SSA) in lymphocytes and the purified bovine Ro(SSA) suggested by the ELISA using the heteroantiserum makes it possible to calculate copies for the lymphocytes. However, the lack ofa suitable standard, and the difference in apparent antigenic structure of the Ro(SSA) in the red cell, suggested by the difference in relative amounts in assays reflecting native and denatured forms of the antigen, do not permit a calculation of copy number.
Although differences have been noted in antigenicity and Ro(SSA) RNA populations across species lines (4, 5, 8) , we report a difference between cell types in the same species. Hendrick et al. reported no difference in the RNA populations associated with Ro(SSA) in erythroleukemia and B-lymphocyte cell lines from mice (4) . The different findings here may suggest a species different, because murine lymphocytes are reported to have only two RNA species, compared with four for humans (4) . Alternately, a difference in actively dividing neoplastic cells in erythroleukemia and the anucleated nondividing cells used here may play a role. There is not only a difference in the number of different RNA populations, but only one is of a similar size to that in lymphocytes (hY4). Whether this comigrating RNA is identical in sequence remains to be determined. Note also that the relative amounts of these two RNA species in red cells is similar to that seen with hY4 and hY5 in nucleated human cells. This difference in relative amounts also lends support to the existence of Ro(SSA) in red cells, as opposed to contamination from lymphocytes. These differing RNA populations may suggest heterogeneity of the Ro(SSA) protein.
Other investigators have reported different molecular weights for Ro(SSA) (9, 14, 22, 24, 25) . Recently, there has been a report of two different molecular forms in the lymphocyte (26) . Both forms have been described before, but the smaller protein was thought to be a degradation product (9) . Ben-Chetrit et al. showed that antibodies from some SS patients would preferentially bind to the 60-kD form, whereas others would only bind the 52-kD form (26) . The two forms reported here differ from the two molecular types in lymphocytes. The common 60-kD form in the two cell types appears to be antigenically different in that some sera bind the 60-kD form in the red cell and not the lymphocyte and vice versa. This reciprocal antigenic difference shows that the two 60-kD molecules are structurally different. The molecular weight differences previously thought to be the result of differential degradation are shown here to represent alternate antigenic forms in the lymphocyte and the red cell. The binding of different sera with different molecular forms may suggest a reason for the variability in the molecular weight of Ro(SSA) from 50 to 61 kD that have been reported using anti-Ro(SSA) from different patients with different fine specificities (9, 14, 23, 25) .
Reconciling the presence of multiple forms of Ro(SSA) with the finding of a single line of identity in immunodiffusion is a question requiring further investigation. Nonreducing SDS-polyacrylamide gels of the eluted precipitins from counterimmunoelectrophoresis showed the precipitins to be composed of a 60-kD protein (data not presented). One explanation is that only the antibodies to the common epitopes are precipitating antibodies. The existence of nonprecipitating antibodies has been described in other systems (27) . Whether such nonprecipitating antibodies exist in the sera of these patients is under study in our laboratory.
Additional evidence for the existence of separate gene products in red cells and lymphocytes is seen in the ELISA data with the two heteroantisera, the rabbit antibovine Ro(SSA) and the rabbit antihuman red cell Ro(SSA), respectively. The ability ofthese antisera to distinguish the two forms indicates two antigenically distinct groups.
Other evidence that was not reported here further supports the existence of different forms of Ro(SSA) in the red cell. We have observed a difference in susceptibility to chaotropic agents with Ro(SSA) from the two cell types. The antigen activity of Ro(SSA) from red cells as measured by ELISA is more easily destroyed by chaotropic agents than is Ro(SSA) from lymphocytes. Also, Ro(SSA) from red cells is antigenically less active than lymphocyte Ro(SSA) in native Western blots of isoelectric focusing gels when comparable amounts of Ro(SSA), as determined by ELISA, are used. This parallels the lesser antigenicity in red cell Ro(SSA) compared with lymphocyte Ro(SSA) in other assays reflecting native antigen structure such as gel diffusion, and Staphylococcus aureus-assisted immunoprecipitation. Western blots of SDS polyacrylamide gels show similar amounts of Ro(SSA) in red cells when compared with lymphocytes. These differential antigenic properties reflect the molecular differences among the Ro(SSA) proteins from these two cell types.
In summary, we have presented evidence that red blood cells contain at least two Ro(SSA) particles and they are different from the two Ro(SSA) particles in lymphocytes. These differences include different associated RNAs in different relative amounts, different antigenic proteins detected by Western blot, and differing antigenicity in ELISA using heteroantisera. These differences in aggregate are best explained by the existence of separate gene products for the Ro(SSA) protein in lymphocytes and red blood cells. Whether these newly described forms of Ro(SSA) in the red cell, which are extremely active in the denatured state in Western blots, play a role in the pathophysiology of SLE and SS is a question for future research.
